Prucalopride
Patient w/ history of arrhythmias or ischaemic CV disease, severe and unstable concomitant disease (e.g. cancer, AIDS, neurological or psychiatric, pulmonary, IDDM or other endocrine disroders). Severe hepatic (Child-Pugh Class C) and renal (GFR <30 mL/min/1.73 m2) impairment. Elderly. This drug may cause dizziness and fatigue, if affected, do not drive or operate machinery. Monitoring Parameters: Monitor bowel movement frequency.
Chronic idiopathic constipation
Intestinal obstruction or perforation, obstructive ileus, active severe inflammatory bowel conditions (e.g. Crohn’s disease, toxic megacolon/megarectum, and ulcerative colitis). Renal impairment requiring dialysis. Pregnancy and lactation.
N/A
Nervous: Headache, dizziness, fatigue, malaise, tremors. CV: Palpitations. GI: Nausea, abdominal pain and distention, diarrhoea, vomiting, flatulence, dyspepsia, anorexia, rectal bleeding, gastroenteritis. Genitourinary: Polyuria, pollakiuria. Musculoskeletal: Muscle spasm. Others: Fever.
Prucalopride is a selective 5-HT4 receptor agonist w/ prokinetic effect. It stimulates peristaltic reflex, intestinal secretions, and GI motility.
May decrease serum concentration of contraceptives (i.e. oestrogens, progestins). May enhance adverse effect of levosulpiride. Increased serum concentration w/ P-glycoprotein/ABCB1 inhibitors. Reduced effect w/ atropine-like substance.
Pregnancy Available data from case reports with use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, major birth defects, or adverse maternal or fetal outcomes Animal data In animal reproduction studies, no adverse developmental effects were observed with prucalopride during organogenesis in pregnant rats and rabbits at doses up to ~390x and 780x, respectively, the recommended human dose of 2 mg/day Lactation Prucalopride is present in breast milk No data are available of effects on breastfed children or milk production Consider developmental and health benefits of breastfeeding along with the mother’s clinical need and any potential adverse effects on the breastfed child from prucalopride or from the underlying maternal condition
Oral Chronic idiopathic constipation Adult: 2 mg once daily. Elderly: Initially, 1 mg once daily, may increase to 2 mg once daily if necessary. Hepatic Impairment Severe (Child-Pugh Class C): Initially, 1 mg once daily, may increase to 2 mg once daily if necessary.
N/A
Severe (GFR <30 mL/min/1.73 m2): 1 mg once daily. Patient on dialysis: Contraindicated.
May be taken with or without food.
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.